Fate Therapeutics, Inc.
NASDAQ•FATE
CEO: Dr. Bahram Valamehr M.B.A., Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2013-10-01
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Contact Information
Market Cap
$136.03M
P/E (TTM)
-1.0
17.9
Dividend Yield
--
52W High
$1.94
52W Low
$0.66
52W Range
Rank62Top 92.6%
1.9
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.9 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$1.37M+0.00%
4-Quarter Trend
EPS
-$0.27+0.00%
4-Quarter Trend
FCF
-$24.51M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Net Loss Significantly Reduced Net loss narrowed to $(136.3) M in 2025 from $(186.3) M in 2024; R&D expenses decreased $27.2 M.
Collaboration Revenue Decline Collaboration revenue dropped $7.0 M to $6.6 M in 2025, reflecting milestone achievement timing in prior year.
FT819 Autoimmunity Pipeline Advances FT819 received RMAT designation; Phase 1 trial ongoing for SLE, showing deep B-cell depletion data.
Cash Position Strengthened Cash, equivalents, and restricted cash totaled $56.9 M as of December 31, 2025, up from $46.3 M.
Risk Factors
Substantial Funding Required Operations require substantial additional funding; failure to secure capital risks delaying development or commercialization efforts.
Complex Manufacturing Hurdles iPSC-derived cell therapy manufacturing is complex, subject to scale-up issues, quality control, and supply chain risks.
Stock Price Volatility Risk Stock price subject to fluctuation; principal stockholders own 40.1% and may exert significant control over company.
Regulatory Approval Uncertainty Novel product candidates face uncertain regulatory approval pathways, potentially requiring costly additional clinical studies.
Outlook
Advance Autoimmune Disease Trials Plan to continue FT819 multi-center Phase 1 trial expansion across SLE, SSc, AAV, and IIM indications.
Progress Solid Tumor Candidates Continue advancing FT825 (HER2) and FT836 (MICA/MICB) Phase 1 trials for advanced solid tumors.
Complete IND-Enabling Activities Completing IND-enabling activities for FT839 in 2026 to support initial clinical investigation for dual-CAR therapy.
Seek Strategic Partnerships Focus on forming new partnerships for research, development, and commercialization of iPSC-derived cell therapies.
Peer Comparison
Revenue (TTM)
$36.93M
$21.05M
$13.11M
Gross Margin (Latest Quarter)
100.0%
80.4%
63.8%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| PEPG | $368.04M | -4.1 | -75.7% | 9.8% |
| FBRX | $334.97M | -9.2 | -75.6% | 0.0% |
| ALEC | $242.80M | -1.6 | -225.0% | 12.4% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-5.6%
Growth Under Pressure
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention
Deep Research
Next earnings:May 6, 2026
EPS:-$0.28
|Revenue:$1.22M
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data